[go: up one dir, main page]

EP1317247A1 - Traitement cosmetique de la peau et/ou des cheveux - Google Patents

Traitement cosmetique de la peau et/ou des cheveux

Info

Publication number
EP1317247A1
EP1317247A1 EP00963378A EP00963378A EP1317247A1 EP 1317247 A1 EP1317247 A1 EP 1317247A1 EP 00963378 A EP00963378 A EP 00963378A EP 00963378 A EP00963378 A EP 00963378A EP 1317247 A1 EP1317247 A1 EP 1317247A1
Authority
EP
European Patent Office
Prior art keywords
composition
cosmetic
phase
biologically active
enzyme
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00963378A
Other languages
German (de)
English (en)
Inventor
Conor James O'prey
Dorothea Luise Niklas
William Joseph Darby
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Procter and Gamble Co
Original Assignee
Procter and Gamble Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter and Gamble Co filed Critical Procter and Gamble Co
Publication of EP1317247A1 publication Critical patent/EP1317247A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/88—Two- or multipart kits
    • A61K2800/884—Sequential application
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations

Definitions

  • the cosmetic method of the present invention comprises administering, through phase one of the treatment regimen cycle, one or more doses of a cosmetic composition comprising a biologically active enzyme, wherein the biologically active enzyme is stably formulated.
  • compositions useful herein comprise one or more enzymes selected from lipases, phospholipases, glycosidases, lactoperoxidases and cellulases, and mixtures thereof.
  • Cosmetic compositions for use in phase one of the treatment method comprise from about 0.0001% to about 10%, more preferably from about 0.001% to about 5%, even more preferably from about 0.005% to about 1%, and most preferably from about 0.005% to about 0.5%, by weight, of the biologically active enzyme.
  • Protease enzymes are the highly preferred biologically active compound for use herein.
  • protease enzymes are classified under the Enzyme Classification number E.C. 3.4 (Carboxylic Ester Hydrolases) in accordance with the Recommendations (1992) ofthe International Union of Biochemistry and Molecular Biology (TUBMB).
  • Useful proteases are also described in PCT publications: WO 95/30010 published November 9, 1995 by The Procter & Gamble Company; WO 95/30011 published November 9, 1995 by The Procter & Gamble Company; WO 95/29979 published November 9, 1995 by The Procter & Gamble Company.
  • Preferred protease enzymes for use herein are subtilisin, chymotrypsin and elastase-type protease enzymes.
  • the type of carrier ultilised in the present invention depends on the type of product form desired for the composition.
  • the topical compositions useful in the subject invention may be made into a wide variety of product forms such as are known in the art. These include, but are not limited to, lotions, creams, gels, sticks, ointments, pastes and mousses. These product forms may comprise several types of carriers including, but not limited to, solutions, emulsions, and gels.
  • Preferred carriers comprise an emulsion comprising a hydrophilic phase, especially an aqueous phase, and a hydrophobic phase e.g., a lipid, oil or oily material.
  • a hydrophilic phase will be dispersed in the hydrophobic phase, or vice versa, to form respectively hydrophilic or hydrophobic dispersed and continuous phases, depending on the composition ingredients.
  • the term "dispersed phase” is a term well-known to one skilled in the art which means that the phase exists as small particles or droplets that are suspended in and surrounded by a continuous phase.
  • the dispersed phase is also known as the internal or discontinuous phase.
  • Preferred humectants include, but are not limited to, compounds selected from urea, D or DL panthenol, calcium pantothenate, royal jelly, panthetine, pantotheine, panthenyl ethyl ether, pangamic acid, pyridoxin, pantoyl lactose Vitamin B complex, hexane - 1, 2, 6, - triol, guanidine or its derivatives.
  • Highly preferred humectants are urea, panthenol and mixtures thereof. The above listed compounds may be incorporated singly or in combination.
  • compositions herein preferably contain an emulsifier and/or surfactant, generally to help disperse and suspend the disperse phase within the continuous aqueous phase.
  • a surfactant may also be useful if the product is intended for skin cleansing.
  • emulsifiers will be referred to under the term 'surfactants', thus 'surfactant(s)' will be used to refer to surface active agents whether used as emulsifiers or for other surfactant purposes such as skin cleansing.
  • Known or conventional surfactants can be used in the composition, provided that the selected agent is chemically and physically compatible with essential components of the composition, and provides the desired characteristics. Suitable surfactants include non-silicone derived materials, and mixtures thereof. All surfactants discussed in application WO 00/24372 should be considered as suitable for use in the present invention.
  • An emulsifier for use herein is most preferably a fatty acid ester blend based on a mixture of sorbitan fatty acid ester and sucrose fatty acid ester, especially a blend of sorbiton stearate and sucrose cocoate.
  • This is commercially available from ICI under the trade name Arlatone 2121.
  • Even further suitable examples include a mixture of cetearyl alcohols, cetearyl glucosides such as those available under the trade name Montanov 68 from Seppic and Emulgade PL68/50 available from Henkel..
  • compositions of the invention can also contain from about 0.01% to about 10%, preferably from about 0.1% to about 5% of a panthenol moisturizer.
  • the panthenol moisturizer can be selected from D-panthenol ([R]-2,4-dihydroxy-N-[3-hydroxypropyl)]- 3,3-dimethylbutamide), DL-panthenol, calcium pantothenate, royal jelly, panthetine, pantotheine, panthenyl ethyl ether, pangamic acid, pyridoxin, and pantoyl lactose.
  • a safe and effective amount of an anti-inflammatory agent may be added to the compositions of the subject invention, preferably from about 0.1 %> to about 5%>, more preferably from about 0.1 %> to about 2%, of the composition.
  • the anti-inflammatory agent enhances the skin appearance benefits of the present invention, e.g., such agents contribute to a more uniform and acceptable skin tone or colour.
  • the exact amount of anti-inflammatory agent to be used in the compositions will depend on the particular anti- inflammatory agent utilised since such agents vary widely in potency.
  • compositions preferably comprise from about 0.1% to about 10%, more preferably from about 0.2%o to about 5%>, also preferably from about 0.5%> to about 2%>, of a skin lightening agent.
  • Suitable skin lightening agents include those known in the art, including kojic acid, arbutin, ascorbic acid and derivatives thereof, e.g., magnesium ascorbyl phosphate.
  • Further skin lightening agents suitable for use herein also include those described in WO 95/34280 and WO 95/23780; each incorporated herein by reference.
  • the dispensing system simultaneously dispenses the biologically active composition and the placebo composition together, in a highly preferred embodiment that this occurs through a single nozzle, and that during phase two the dispensing system dispenses only the placebo composition.
  • the single dispensing system can be adapted to comprise enough material such that it is able to alternate between phase one and phase two of the treatment method for a period of one or more different treatment cycles.
  • the single dispensing system comprises enough material such that at the end of phase one no further cosmetic composition comprising biologically active material remains and that at the end of phase two no further placebo composition remains.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Cosmetics (AREA)

Abstract

L'invention concerne un traitement cosmétique de la peau et/ou des cheveux, lequel comprend un schéma posologique de traitement à au moins deux cycles, un cycle unique consistant: (a) à administrer, comme phase une, pendant une durée comprise entre 1 et 365 jours, au moins une dose unitaire d'une première composition cosmétique topique renfermant une enzyme active sur le plan biologique, cette enzyme étant de formulation stable; puis (b) à administrer, comme phase deux, pendant une durée comprise entre 1 et 365 jours, au moins une dose unitaire d'une composition cosmétique topique de placebo. Ce traitement cosmétique permet au fabricant de réguler le niveau d'exposition des clients à un composé actif sur le plan biologique et également de conférer à la peau ou aux cheveux douceur et souplesse.
EP00963378A 2000-09-13 2000-09-13 Traitement cosmetique de la peau et/ou des cheveux Withdrawn EP1317247A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2000/024979 WO2002022099A1 (fr) 2000-09-13 2000-09-13 Traitement cosmetique de la peau et/ou des cheveux

Publications (1)

Publication Number Publication Date
EP1317247A1 true EP1317247A1 (fr) 2003-06-11

Family

ID=21741766

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00963378A Withdrawn EP1317247A1 (fr) 2000-09-13 2000-09-13 Traitement cosmetique de la peau et/ou des cheveux

Country Status (6)

Country Link
EP (1) EP1317247A1 (fr)
JP (1) JP2004509861A (fr)
CN (1) CN1468087A (fr)
AU (1) AU2000274801A1 (fr)
MX (1) MXPA03002166A (fr)
WO (1) WO2002022099A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090017080A1 (en) * 2007-03-15 2009-01-15 Paul Robert Tanner Personal care kit having skin care compositions with a readily perceptible difference
FR2937512B1 (fr) * 2008-10-23 2012-11-16 Oreal Systeme cosmetique comportant un systeme de reglage d'une caracteristique d'un produit en fonction d'une information d'horloge
CN104434728A (zh) * 2014-11-15 2015-03-25 柳州市康小乐牛奶有限公司 一种马奶护手霜
US9956151B2 (en) * 2015-03-05 2018-05-01 Avon Products, Inc. Methods for treating skin
US10076479B1 (en) 2018-05-08 2018-09-18 Avon Products, Inc. Methods for treating skin
CN108272823A (zh) * 2018-01-24 2018-07-13 北京臻溪谷医学研究中心（有限合伙） 一种胎盘亚全能干细胞与间充质干细胞混合培养提取物的修复制剂及其制备方法
WO2022020332A1 (fr) 2020-07-21 2022-01-27 Chembeau LLC Formulations cosmétiques à base de diester et leurs utilisations
CN115317399A (zh) * 2022-07-07 2022-11-11 湖北真福医药有限公司 一种抗衰老组合物及其制备方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK149832C (da) * 1981-07-17 1987-05-18 Riemann Claus Antiperspirantpraeparat bestaaende af to komponenter
ATE114473T1 (de) * 1984-04-30 1994-12-15 Procter & Gamble Ausrüstung für die verwendung bei der behandlung von osteoporose.
GB9207280D0 (en) * 1992-04-02 1992-05-13 Unilever Plc Skin care method and composition
EP0817613B1 (fr) * 1996-01-31 2005-03-30 Cosmoferm B.V. Utilisation de compositions comprenant des enzymes stabilises
JP2002515903A (ja) * 1997-02-12 2002-05-28 ジョンソン・アンド・ジョンソン・コンシューマー・カンパニーズ・インコーポレイテッド セリンプロテアーゼと局所レチノイドの組成物
IE990935A1 (en) * 1999-11-08 2002-04-03 Procter & Gamble Cosmetic Compositions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0222099A1 *

Also Published As

Publication number Publication date
CN1468087A (zh) 2004-01-14
JP2004509861A (ja) 2004-04-02
WO2002022099A1 (fr) 2002-03-21
AU2000274801A1 (en) 2002-03-26
MXPA03002166A (es) 2003-07-24

Similar Documents

Publication Publication Date Title
US20030206897A1 (en) Cosmetic compositions
US20030157088A1 (en) Compositions containing enzymes stabilized with inhibitors having certain binding properties and methods for using such compositions in personal care
CA2441595C (fr) Proteines provoquant une reaction immunogene modifiee, et methodes de production et d'utilisation desdites proteines
US20030175232A1 (en) Compositions containing enzymes stabilized with certain osmo-protectants and methods for using such compositions in personal care
WO2001034111A1 (fr) Compositions cosmetiques
WO2002022099A1 (fr) Traitement cosmetique de la peau et/ou des cheveux
WO2002022102A1 (fr) Compositions cosmetiques
US20030211068A1 (en) Cosmetic method
EP1317248A1 (fr) Procede cosmetique
IE990934A1 (en) Cosmetic Compositions
US20030206896A1 (en) Cosmetic method
WO2002022103A1 (fr) Compositions cosmetiques
EP1317246A1 (fr) Traitement cosmetique
MXPA02004611A (es) Composiciones cosmeticas que se dejan en la piel que comrpenden en alcohol polihidrilico y un emulsificante que forma cristales liquidos.
HK1061566B (en) Proteins producing an altered immunogenic response and methods of making and using the same

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030328

AK Designated contracting states

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

RIN1 Information on inventor provided before grant (corrected)

Inventor name: DARBY, WILLIAM, JOSEPH

Inventor name: NIKLAS, DOROTHEA, LUISE

Inventor name: O'PREY, CONOR, JAMES

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20050331